Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to  -adrenergic agents.
In an effort to better define the role of betaadrenergic blockade in human bronchial asthma, peripheral blood leukocytes and lymphocytes from individuals with this condition were studied for possible alterations in cyclic AMP metabolism. Using a previously described radioimmunoassay to measure cyclic AMP, cells from asthmatic subjects were shown to have a highly significant decrease in their cyclic AMP response to beta-adrenergic agents (isoproterenol, norepinephrine, and epinephrine) by comparison with normal control cells. The alteration in responsiveness was most marked at the time of severe active asthma and returned toward normal during periods of clinical remission. Evidence was presented to indicate that the reduced response in cells from asthmatic individuals was not due to marked alterations in the proportion of T and B lymphocytes. Five normal volunteers were treated with an oral bronchodilator preparation containing theophylline and ephedrine over a 2 wk period without a significant change in the lymphocyte cyclic AMP response. These results provide unambiguous evidence for altered adrenergic responsiveness in bronchial asthma and indicate that purified peripheral blood lymphocytes should be a suitable in vitro system for further elucidation of the abnormality. Despite the reduction in catecholamine responsiveness in the asthmatic population as a whole, major alterations were largely restricted to individuals with severe, chronic asthma. Conclusive evidence for beta-adrenergic blockade in individuals who have not had recent asthmatic symptoms was not obtained, casting some doubt on the theory that bronchial asthma is due to a congenital derangement of cyclic AMP metabolism. Moreover, transient episodes of bronchospasm were often accompanied by a normal cyclic AMP response indicating that episodes of asthma frequently occur in the absence of easily demonstrable adrenergic blockade.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D001249:Asthma / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D002478:Cells, Cultured; D002499:Centrifugation, Density Gradient; D000242:Cyclic AMP / Q000097:blood / Q000378:metabolism*; D004837:Epinephrine / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007545:Isoproterenol / Q000494:pharmacology; D007962:Leukocytes / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism; D008214:Lymphocytes / Q000032:analysis / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D011863:Radioimmunoassay; D013147:Spirometry; D013806:Theophylline / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013806:Theophylline; D000242:Cyclic AMP; D007545:Isoproterenol; D009638:Norepinephrine; D004837:Epinephrine